As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

A growing number of couples are choosing to delay parenthood in pursuit of career milestones, financial stability, and personal goals. But ...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

India Pharma Conference: India is set to become a global leader in advanced medicines like biologics and biosimilars, Union Minister J P Na...

Zydus Lifesciences has introduced Anyra, its first indigenously developed biosimilar for the treatment of visual impairment in India. This ...

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars l...

In his video address to the National Summit on Quality of Biologicals, organised here by the National Institute of Biologicals (NIB), the m...

Renowned oncologist, cancer researcher and Pulitzer Prize-winning author Dr Siddhartha Mukherjee’s latest book The Song of The Cell: An Exp...

Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- develo...

"ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is in global clinical development ...

Biocon Biologics said it aims to deliver substantial savings to healthcare systems by enhancing access and availability of these high-quali...

Biocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for ...

The biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervic...

Biologics, also called biopharmaceuticals, have revolutionised treatment in chronic and serious illnesse and nudged traditional drugs out o...

Public health groups globally have slammed it on grounds that it gives monopoly protection to pharma companies, especially for biologic dru...

Aarin Capital, Accel Partners, IDG Ventures as well as Karnataka state government-backed KITVEN have invested Rs 27.5 crore in Theramyt Nov...